Market Intelligence, Clinical Progress, and High-Purity Reagents for Angelman Syndrome, dup15q Syndrome, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for UBE3A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | UBE3A Full-Length / HECT Domain Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View UBE3A Products |
| Mutant Panel | UBE3A C843A (Catalytic Dead) / Angelman Mutants For mechanism and specificity controls. Sequence Verified. |
View UBE3A Products |
| Gene Delivery | UBE3A Promise-ORF / Lentivirus Full-length ORF for stable cell lines and ASO mechanism studies. |
View UBE3A Products |
| Benchmark Ab | Anti-UBE3A Antibody (Clone 330-30) Recombinant positive control for western blot and IHC. |
View UBE3A Products |
| Validator | UBE3A siRNA Set For knockdown verification and loss-of-function studies. |
View UBE3A Products |
| Related Target A | TP53 Downstream target degraded by UBE3A in HPV-induced malignancies. |
View TP53 Products |
| Related Target B | SNRPN Key imprinted gene cluster partner for Angelman Syndrome models. |
View SNRPN Products |
| Related Target C | GABRB3 Downstream synaptic target in Angelman pathway; complementary CNS target. |
View GABRB3 Products |
| Related Target D | CDKL5 Neurodevelopmental disorder target with overlapping indication strategy. |
View CDKL5 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species translation (Mouse to Cyno) | Human/Mouse/Cyno ortholog proteins available with >95% purity and Theoretical MW confirmed. |
| E3 Ligase Screening Structural Integrity | Recombinant proteins meticulously expressed with Native Glycosylation and Sequence Verified. |
| Lack of Reliable Controls | Clinical Benchmark Antibodies included for rigorous assay standardization. |
| False Positives in Gene Silencing | Validated siRNA included for specificity checks and target deconvolution. |
| HECT Domain Activity Validation | High-purity HECT domain (>95%) with validated auto-ubiquitination capacity. |
| Catalytic Dead Controls | C843A mutant protein (Cys-to-Ala) for negative control in enzymatic assays. |
| Cell-Based ASO Screening | Lentivirus particles for stable UBE3A reporter cell line construction. |
| Substrate Competition Studies | Full-length WT and mutant proteins for binding affinity determination (SPR/ITC). |
Live UBE3A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for UBE3A therapeutics is intensifying, with major players shifting focus from traditional symptom management to genetic modifiers, primarily Antisense Oligonucleotides (ASOs), Gene Therapies, and targeted degradation strategies. In Angelman Syndrome, the strategy centers on un-silencing the paternal UBE3A allele. Conversely, in oncology and dup15q syndrome, the goal is targeted inhibition or degradation of overexpressed UBE3A. As first-generation ASOs reach the clinic, the next wave of R&D is targeting highly specific delivery vectors, PROTACs utilizing UBE3A as an E3 ligase, selective small molecule inhibitors, and refined gene therapy approaches.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ASO / RNAi | Ionis Pharmaceuticals, Biogen, Ultragenyx, Roche | Angelman Syndrome | Expression Validation (Need specific Abs and siRNA sets); Stable reporter cell lines for ASO screening (Lentivirus). |
| Gene Therapy (AAV) | Taysha Gene Therapies, PTC Therapeutics, FAST | Angelman Syndrome | Viral Titer & Expression (Need high-purity WT proteins for standard curves); Immunogenicity assays (ADA detection). |
| Small Molecule Inhibitor | Novartis, Various Academic Labs | Oncology (HPV+), dup15q | Selectivity Assay (Need Sequence Verified ligase proteins); Enzymatic Activity Assay (WT vs C843A mutant). |
| PROTACs / Molecular Glue | Arvinas, Kymera, C4 Therapeutics | Oncology (Targeted Protein Degradation) | Ternary Complex Validation (Need pure UBE3A Recombinant Proteins); E2 Binding Assays for complex formation. |